Payment overview · 2025
General Payments
$1,198.59
48 reported records · 17 companies
Healthcare provider profile · identity verified
Raymond Eugene Tidman, MD
Allopathic & Osteopathic Physicians|Family Medicine · BLUE RIDGE, GA · NPI 1588663686
Verified facts
What the public records show
CMS Open Payments records show Raymond Eugene Tidman, MD received $1,198.59 in general payments during 2025 across 48 reported records.
Corcept Therapeutics accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Mounjaro, Ozempic, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Xyosted by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $232.62 | 19.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $191.79 | 16.0% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $186.88 | 15.6% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $125.14 | 10.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.12 | 5.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.51 | 5.1% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $58.42 | 4.9% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $38.49 | 3.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.90 | 3.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.28 | 3.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.80 | 3.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.65 | 2.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.11 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.94 | 1.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.27 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.91 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.76 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,198.59 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $232.62 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $167.46 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $151.77 | 10 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $135.28 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $125.14 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $58.42 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $52.28 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.60 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $38.49 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.90 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.75 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.28 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.97 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 179 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 160 | exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
104 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
179 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 467 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 396 | 81 |
| Omeprazole | Omeprazole | 233 | 50 |
| Gabapentin | Gabapentin | 231 | 37 |
| Atorvastatin Calcium | Atorvastatin Calcium | 210 | 52 |
| Eliquis | Apixaban | 179 | 24 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 178 | 20 |
| Alprazolam | Alprazolam | 172 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 52 |
| Ozempic | Semaglutide | 160 | 26 |
| Furosemide | Furosemide | 136 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 122 | 35 |
| Metformin Hcl | Metformin Hcl | 121 | 32 |
| Azithromycin | Azithromycin | 114 | 79 |
| Tramadol Hcl | Tramadol Hcl | 114 | 28 |
| Simvastatin | Simvastatin | 113 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 111 | 29 |
| Clonazepam | Clonazepam | 111 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 109 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 27 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 105 | 13 |
| Carvedilol | Carvedilol | 104 | 25 |
| Xyosted | Testosterone Enanthate | 104 | 18 |
| Lisinopril | Lisinopril | 103 | 30 |
| Farxiga | Dapagliflozin Propanediol | 101 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 21 |
| Losartan Potassium | Losartan Potassium | 95 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 92 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 12 |
| Potassium Chloride | Potassium Chloride | 81 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 15 |
| Mirtazapine | Mirtazapine | 69 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 69 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 12 |
| Repatha Sureclick | Evolocumab | 60 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 12 |
| Allopurinol | Allopurinol | 55 | 11 |
| Trazodone Hcl | Trazodone Hcl | 55 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 12 |
| Buprenorphine Hcl | Buprenorphine Hcl | 53 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 12 |
| Prednisone | Prednisone | 51 | 15 |
| Meloxicam | Meloxicam | 49 | 12 |
| Atenolol | Atenolol | 47 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 45 | 14 |
| Finasteride | Finasteride | 45 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 32 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 11 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 16 |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 37 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Gemtesa | Vibegron | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Colchicine | Colchicine | 27 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 23 |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Forteo | Teriparatide | 26 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 14 |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Nystatin | Nystatin | 20 | 11 |
| Testosterone | Testosterone | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Dexamethasone | Dexamethasone | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Tobramycin | Tobramycin | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,198.59 · 48 records | Corcept Therapeutics | Auvelity, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, KISUNLA, Korlym, LEQVIO, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, Wegovy, XYOSTED, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error